- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Erenumab: A Potential Breakthrough in Rosacea Management
Denmark: A nonrandomized controlled trial showed the importance of the calcitonin gene-related peptide (CGRP) pathway in the pathophysiology of erythema and flushing in rosacea. The findings suggested that calcitonin gene-related peptide receptor inhibition holds potential in treating rosacea-associated erythema and flushing.
"The study comprising 30 individuals with rosacea-associated flushing and erythema found that subcutaneous injections of monoclonal antibodies against the calcitonin gene-related peptide receptor administered every four weeks for 12 weeks significantly decreased days with erythema and flushing by weeks 9 through 12 compared with baseline," the researchers reported. The findings were published online in JAMA Dermatology on April 17, 2024.
Rosacea is characterized by facial redness, visible blood vessels, and in some cases, papules and pustules. Persistent erythema and flushing are hallmark features, often resistant to conventional therapies. This affects patients' physical appearance and psychological well-being, highlighting the need for effective treatment options.
While several treatment modalities exist, managing these symptoms remains a challenge. However, recent research suggests a promising avenue with erenumab use, a monoclonal antibody targeting CGRP. Nita K. F. Wienholtz, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark, and colleagues aimed to examine the tolerability, effectiveness, and safety of erenumab, an anti–CGRP-receptor monoclonal antibody, for the treatment of rosacea-associated erythema and flushing.
For this purpose, the researchers conducted a single-center, open-label, single-group, nonrandomized controlled trial between 2020 and 2021. Eligible participants included patients with rosacea with at least 15 days of either moderate to severe erythema and/or moderate to extreme flushing. Throughout the study period, no concomitant rosacea treatment was allowed.
Participants received 140 mg of erenumab subcutaneously every four weeks for 12 weeks. At week 20, a safety follow-up was performed. A total of 30 participants (mean age, 38.8 years; 77% females were included, of whom 27 completed the 12-week study.
The primary outcome was a mean change in the number of days with moderate to extreme flushing during weeks 9 through 12, compared with the 4-week run-in period (baseline). The secondary outcome was a mean change in the number of days with moderate to severe erythema. Adverse events were recorded for patients who received at least one dose of erenumab.
Following were the study’s key findings:
- There was a reduction in the mean number of days with moderate to extreme flushing by −6.9 days from 23.6 days at baseline.
- There was a reduction in the mean number of days with moderate to severe erythema by −8.1 days from 15.2 days at baseline.
- Adverse events included transient mild to moderate constipation (33% of participants), transient worsening of flushing (13% of participants), bloating (10% of participants), and upper respiratory tract infections (10% of participants), consistent with previous data.
- One participant discontinued the study due to a severe adverse event (hospital admission due to gallstones deemed unrelated to the study), and 2 participants withdrew consent due to lack of time.
In conclusion, the findings suggest that erenumab might be effective in reducing rosacea-associated flushing and chronic erythema (participants generally tolerated the treatment well, which was consistent with previous data). The study also showed that CGRP-receptor inhibition holds potential in treating flushing and erythema associated with rosacea.
"Larger randomized clinical trials are needed to confirm this finding," the researchers wrote.
Reference:
Wienholtz NKF, Christensen CE, Do TP, et al. Erenumab for Treatment of Persistent Erythema and Flushing in Rosacea: A Nonrandomized Controlled Trial. JAMA Dermatol. Published online April 17, 2024. doi:10.1001/jamadermatol.2024.0408
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751